EUVIMEDAtrasti EUVIMED
Crossref

Intranasal Insulin for the Treatment of Persistent Post‐COVID‐19 Olfactory Dysfunction

Giancarlo B Cherobin iD, Roberto E S Guimarães, Márcia C de Paula Gomes, Luís O G Vasconcelos, Lígia A N de Abreu

Otolaryngology–Head and Neck Surgery · 2023

DOI: 10.1002/ohn.352 ↗

At a glance

Journal article in Otolaryngology–Head and Neck Surgery, 2023. Written by Giancarlo B Cherobin and 4 co-authors. Institution: Department of Ophthalmology and Otolaryngology, Medical School of Federal University of Minas Gerais, Belo Horizonte, Brazil. Major MEDLINE topics: COVID-19, Olfaction Disorders. Cited 5 times so far (Crossref); 22 references.

SantraukaSubjectsBibliografiniai duomenysCiteRelated studies

Abstract (original language)

Objective

To investigate if intranasal insulin could be a treatment option for those suffering from recalcitrant olfactory dysfunction due to COVID‐19. Study Design Prospective interventional cohort with a single group.

Setting

Sixteen volunteers with anosmia, severe hyposmia, or moderate hyposmia for more than 60 days as sequelae of severe acute respiratory syndrome coronavirus 2 infections were selected for the study. All volunteers reported that standard therapies, such as corticosteroids, have failed to improve their olfactory function.

Methods

Olfactory function was assessed by the Chemosensory Clinical Research Center test of olfaction (COT) before and after the intervention. Changes in qualitative, quantitative, and global COT scores were investigated. The insulin therapy session consisted of placing into each olfactory cleft 2 pieces of gelatin sponge soaked with neutral protamine Hagedorn (NPH) insulin, 40 IU on each side. The procedure was repeated twice a week for 1 month. Glycaemic blood level was measured before and after each session.

Results

The qualitative COT score rose 1.53 points, p = .0001, 95% confidence interval (CI) (−2.12 to −0.94). The quantitative COT score increased by 2.00 points, p = .0002, 95% CI (−3.59 to −1.41). Global COT score had an improvement of 2.01 points, p = .00003, 95% CI (−2.7 to −1.3). Glycaemic blood level dropped on average 10.4 mg/dL, p < .00003, 95% CI (8.1‐12.8).

Conclusion

Our results suggest that the administration of NPH insulin into the olfactory cleft yields a rapid improvement in the sense of smell of patients suffering from persistent post‐COVID‐19 olfactory dysfunction. Moreover, the procedure seems to be safe and tolerable.

Subjects

MeSH terms (MEDLINE)

COVID-19Olfaction DisordersHumansSmellInsulinAnosmiaProspective Studies

Author keywords

COVID-19insulinolfactionsmell

Substances

Insulin

Authors and institutions

  • Department of Ophthalmology and Otolaryngology, Medical School of Federal University of Minas Gerais, Belo Horizonte, Brazil.
  • Núcleo de Otorrino de Belo Horizonte, Belo Horizonte, Brazil.

ORCID profiles: Giancarlo B Cherobin

Cite

APA

Cherobin, G. B., Guimarães, R. E. S., de Paula Gomes, M. C., Vasconcelos, L. O. G., & de Abreu, L. A. N. (2023). Intranasal Insulin for the Treatment of Persistent Post‐COVID‐19 Olfactory Dysfunction. Otolaryngology–Head and Neck Surgery. https://doi.org/10.1002/ohn.352

Vancouver

Cherobin GB, Guimarães RES, de Paula Gomes MC, Vasconcelos LOG, de Abreu LAN. Intranasal Insulin for the Treatment of Persistent Post‐COVID‐19 Olfactory Dysfunction. Otolaryngology–Head and Neck Surgery. 2023. doi:10.1002/ohn.352

BibTeX
@article{Cherobin2023,
  author = {Cherobin, Giancarlo B and Guimarães, Roberto E S and de Paula Gomes, Márcia C and Vasconcelos, Luís O G and de Abreu, Lígia A N},
  title = {Intranasal Insulin for the Treatment of Persistent Post‐COVID‐19 Olfactory Dysfunction},
  journal = {Otolaryngology–Head and Neck Surgery},
  year = {2023},
  doi = {10.1002/ohn.352}
}
Start for free →